Search and analyze individual stocks with comprehensive metrics
Zealand Pharma A/S
Fundamental Score
Zealand Pharma A/S Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ZEAL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (19.60%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (23.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 13.23 vs Industry: 25.23)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Consistent Growth Track Record (36.90% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (62.94% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (8.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (73.40%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
6 factors identified
Profit Decline Concern (-49.73%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Weak Earnings Growth (-12.34% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Negative Free Cash Flow (₹-5.07 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 2.19%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Logistics Solution Provider sector...
Financial Statements
Comprehensive financial data for Zealand Pharma A/S
About ZEAL
Company Details
ZEAL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Zealand Pharma A/S (ZEAL)?
As of 02 Jan 2026, 04:28 pm IST, Zealand Pharma A/S (ZEAL) is currently trading at ₹99.50. The stock has a market capitalization of ₹132.43 (Cr).
Is ZEAL share price Overvalued or Undervalued?
ZEAL is currently trading at a P/E ratio of 13.23x, compared to the industry average of 25.23x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Zealand Pharma A/S share price?
Key factors influencing ZEAL's price include its quarterly earnings growth (Sales Growth: 0.56%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Zealand Pharma A/S a good stock for long-term investment?
Zealand Pharma A/S shows a 5-year Profit Growth of 62.94% and an ROE of 19.60%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.29 before investing.
How does Zealand Pharma A/S compare with its industry peers?
Zealand Pharma A/S competes with major peers in the Logistics Solution Provider. Investors should compare ZEAL's P/E of 13.23x and ROE of 19.60% against the industry averages to determine its competitive standing.
What is the P/E ratio of ZEAL and what does it mean?
ZEAL has a P/E ratio of 13.23x compared to the industry average of 25.23x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹13 for every ₹1 of annual earnings.
How is ZEAL performing according to Bull Run's analysis?
ZEAL has a Bull Run fundamental score of 51.7/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ZEAL belong to?
ZEAL operates in the Logistics Solution Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zealand Pharma A/S.
What is Return on Equity (ROE) and why is it important for ZEAL?
ZEAL has an ROE of 19.60%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Zealand Pharma A/S generates profits from shareholders' equity.
How is ZEAL's debt-to-equity ratio and what does it indicate?
ZEAL has a debt-to-equity ratio of 0.29, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ZEAL's dividend yield and is it a good dividend stock?
ZEAL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has ZEAL grown over the past 5 years?
ZEAL has achieved 5-year growth rates of: Sales Growth 36.90%, Profit Growth 62.94%, and EPS Growth -12.34%.
What is the promoter holding in ZEAL and why does it matter?
Promoters hold 73.40% of ZEAL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ZEAL's market capitalization category?
ZEAL has a market capitalization of ₹132 crores, placing it in the Small-cap category.
How volatile is ZEAL stock?
ZEAL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ZEAL?
ZEAL has a 52-week high of ₹N/A and low of ₹N/A.
What is ZEAL's operating profit margin trend?
ZEAL has a 5-year average Operating Profit Margin (OPM) of 7.56%, indicating the company's operational efficiency.
How is ZEAL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 0.56% and YoY Profit Growth of -49.73%.
What is the institutional holding pattern in ZEAL?
ZEAL has FII holding of 0.00% and DII holding of 2.19%. Significant institutional holding often suggests professional confidence in the stock.